India reports 37,148 new cases, taking its total count to 11,55,191. The toll rises by 587 to 28,084. Total active cases are now more than 4 lakh.
Coronavirus LATEST Updates:India reports 37,148 new cases, taking its total count to 11,55,191. The toll rises by 587 to 28,084. Total active cases are now more than 4 lakh.
The Serum Institute of India says it will seeking to get the licence to manufacture the vaccine developed at the Oxford University, reports NDTV. The vaccine has been found to be both effective and safe in early trials, according to a study in the medical journal The Lancet.
The total number ofcoronavirus cases crossed 11 lakh with a single-day spike of 40,425 cases on Monday, while the toll rose to 27,497 with 681 new casualties reported. It is the first time the number of new cases registered was above 40,000.
The total tally of 11,18,043 cases includes 3,90,459 active cases and 7,00,087 cured/discharged/migrated patients and the toll. The health ministry said that the recovery rate is now 62.62 percent.
Meanwhile, a vaccine candidate developed at the University of Oxford has shown encouraging results in early human testing and appears to be “safe well-tolerated, and immunogenic”, according to a study published inThe Lancet on Monday.
Oxford’s COVID-19 vaccine produces ‘strong antibodies’, shows initial study
Trials by the Oxford University involving 1,077 people showed that the injection led to them making antibodies and white blood cells that can fight coronavirus. The vaccine, named ‘ChAdOx1 nCoV-19’, has been made from a harmless virus called ‘chimpanzee cold virus’.
“Our preliminary findings show that the candidate ChAdOx1 nCoV-19 vaccine given as a single dose was safe and tolerated, despite a higher reactogenicity profile than the control vaccine, MenACWY,” the researchers, led by Pedro M Folegatti and Katiet Ewer, wrote in the study.
“No serious adverse reactions to ChAdOx1 nCoV-19 occurred. The majority of adverse events reported were mild or moderate in severity, and all were self-limiting,” the study said.
The clinical trials of a potential COVID-19 vaccine on humans began in April. The human vaccine trial has been developed by scientists at Oxford University’s Jenner Institute.
Reportedly, the scientistsalso saidthat they “found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunised”.
The study showed that the vaccine induced strong antibody and T-cell immune responses up to day 56 of the ongoing trial.
“We are seeing good immune response in almost everybody,” said Dr Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.
ICC postpones Men’s T20 World Cup due to COVID-19 pandemic
The International Cricket Council (ICC) announced the postponement of this year’s Men’s T20World Cup in Australia due to the ongoing coronavirus pandemic. The T20 World Cup was slated to be played in Australia from 18 October to 15 November this year.
“The IBC Board (the commercial subsidiary of the ICC) agreed to continue to monitor the rapidly changing situation (regarding coronavirus pandemic) and assess all the information available in order to make a considered decision on future hosts to ensure the sport is able to stage safe and successful global events in 2021 and 2022,” ICC said in a statement.
“The IBC Board will also continue to evaluate the situation in relation to being able to stage the ICC Women’s Cricket World Cup 2021 in New Zealand in February next year. In the meantime, planning for this event continues as scheduled,” the statement added.
ICC Chief Executive Manu Sawhney said their number one priority was to protect the health and safety of everyone involved in the sport.
Delhi seems to have reached COVID-19 peak, says AIIMS chief
Certain areas ofDelhi have hit their peakof the COVID-19 pandemic, while certain other areas in the city are yet to reach the peak, said AIIMS director Dr Randeep Guleria on Monday. He added that there is not much evidence of community transmission happening at the national level.
“Certain areas have hit their peak in COVID-19 cases. Delhi seems to have done so because the cases have declined significantly. Certain areas have yet to reach the peak. They will reach the peak a little later,” Guleria